Novel Tubulin Polymerization Inhibitors Overcome Multidrug Resistance and Reduce Melanoma Lung Metastasis

[1]  A. Sonnenberg,et al.  Tetraspanin CD151 maintains vascular stability by balancing the forces of cell adhesion and cytoskeletal tension. , 2011, Blood.

[2]  C. Robert,et al.  New drugs in melanoma: it's a whole new world. , 2011, European journal of cancer.

[3]  A. Hauschild,et al.  Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[4]  D. Roukos PLX4032 and melanoma: resistance, expectations and uncertainty , 2011, Expert review of anticancer therapy.

[5]  Duane D. Miller,et al.  A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer , 2011, Cancer Chemotherapy and Pharmacology.

[6]  Duane D. Miller,et al.  Drug Metabolism and Pharmacokinetics of 4-Substituted Methoxybenzoyl-aryl-thiazoles , 2010, Drug Metabolism and Disposition.

[7]  Duane D. Miller,et al.  Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. , 2010, Journal of medicinal chemistry.

[8]  T. Satou,et al.  Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway , 2010, Journal of experimental & clinical cancer research : CR.

[9]  E. Pasquier,et al.  MVL-PLA2, a Snake Venom Phospholipase A2, Inhibits Angiogenesis through an Increase in Microtubule Dynamics and Disorganization of Focal Adhesions , 2010, PloS one.

[10]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[11]  Wei Li,et al.  Identifying Novel Molecular Structures for Advanced Melanoma by Ligand-Based Virtual Screening , 2009, J. Chem. Inf. Model..

[12]  Duane D. Miller,et al.  Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. , 2009, Journal of medicinal chemistry.

[13]  Duane D. Miller,et al.  Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3β, 17α, 20-triol and their bioactivity in melanoma cells , 2009, Steroids.

[14]  Jinsong Liu,et al.  Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. , 2008, Cancer research.

[15]  P. Nikolinakos,et al.  The Tyrosine Kinase Inhibitor Cediranib for Non-small Cell Lung Cancer and Other Thoracic Malignancies , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  M. Caraglia,et al.  The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? , 2008, The Journal of investigative dermatology.

[17]  J. Maris,et al.  A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors , 2008, Clinical Cancer Research.

[18]  B. Bhattacharyya,et al.  Anti‐mitotic activity of colchicine and the structural basis for its interaction with tubulin , 2008, Medicinal research reviews.

[19]  Duane D. Miller,et al.  Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. , 2007, Bioorganic & medicinal chemistry letters.

[20]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[21]  Jianping Chen,et al.  Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models , 2007, Cancer Chemotherapy and Pharmacology.

[22]  Steve Y. Cho,et al.  A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors , 2006, Clinical Cancer Research.

[23]  Lei Xu,et al.  GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Jian Ding,et al.  Pseudolarix Acid B, a New Tubulin-Binding Agent, Inhibits Angiogenesis by Interacting with a Novel Binding Site on Tubulin , 2006, Molecular Pharmacology.

[25]  E. Voest,et al.  Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Woltering,et al.  Colchicine and 2-methoxyestradiol Inhibit Human Angiogenesis. , 2005, The Journal of surgical research.

[27]  H. Gourdeau,et al.  Species Differences in Troxacitabine Pharmacokinetics and Pharmacodynamics , 2004, Clinical Cancer Research.

[28]  Patrick A. Curmi,et al.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.

[29]  I. Catalá,et al.  Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material , 2002, The Journal of pathology.

[30]  S. Ng,et al.  Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. , 2000, BioTechniques.

[31]  F. Cognetti,et al.  Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. , 2000, Journal of experimental & clinical cancer research : CR.

[32]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[33]  L. Xue,et al.  Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. , 1999, Cancer biotherapy & radiopharmaceuticals.

[34]  W. Berger,et al.  Possible role of the multidrug resistance‐associated protein (MRP) in chemoresistance of human melanoma cells , 1997, International journal of cancer.

[35]  D. Guénard,et al.  [Taxotere: from yew's needles to clinical practice]. , 1993, Bulletin du cancer.

[36]  G. Jacobsen,et al.  Chemotherapy of a human malignant melanoma transplanted in the nude mouse. , 1975, Cancer research.

[37]  Duane D. Miller,et al.  Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor. , 2011, Cancer research.

[38]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[39]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[40]  S. Cohen Chemotherapy of metastatic melanoma. , 1992, The Mount Sinai journal of medicine, New York.

[41]  S. Salmon Human tumor clonogenic assays: growth conditions and applications. , 1986, Cancer genetics and cytogenetics.

[42]  R. Nelson The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. , 1982, Medical and pediatric oncology.